Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement 
Tesla Poised for Breakout Year in 2026 as New Products and EV Market Reset Drive Growth 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
U.S. Airline Flight Cancellations Surge After Venezuela Military Operation and FAA Airspace Closures 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
NEW YORK, March 14, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased SCYNEXIS, Inc. (NASDAQ:SCYX) securities (1) pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company’s Initial Public Offering on or about May 2, 2014 and/or (2) between May 2, 2014 and March 2, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/scynexis-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) SCYNEXIS’s lead product SCY-078 posed substantial undisclosed health and safety risks; (ii) consequently, the Company had overstated the drug’s approval prospects and/or commercial viability; and (iii) as a result of the foregoing, SCYNEXIS’s public statements were materially false and misleading at all relevant times.
On March 2, 2017, SCYNEXIS announced that the U.S. Food and Drug Administration “informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data” of the formulation. The hold stems from “three mild-to-moderate thrombotic events in healthy volunteers” receiving the formulation.
If you suffered a loss in SCYNEXIS you have until May 8, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/scynexis-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
